CathWorks Receives CPT Code for New Wire-Free, Intraprocedural FFR Measurements to Optimize PCI Therapy Decisions
July 11 2018 - 7:00PM
Business Wire
CathWorks announced the approval of a new CPT code 0523T for
non-invasive, 3D FFRangio™ enabled interpretation of possible
atherosclerotic stenosis during coronary angiography interventions.
The code issuance is a major step forward in helping physicians
objectively and cost-effectively determine if PCI (percutaneous
coronary intervention) is indicated and revascularization has
occurred in every coronary angiography procedure.
This breakthrough in objective intraprocedural decision-making,
is made possible by the development of the CathWorks FFRangio™
System. It is the non-invasive FFR platform that quickly and
precisely delivers objective multi-vessel physiologic measurements
to cost-effectively optimize and confirm intraprocedural PCI
therapy decisions.
CPT code 0523T enables healthcare providers using the CathWorks
FFRangio™ System to be reimbursed for:
Intraprocedural coronary fractional flow
reserve (FFR) with 3D functional mapping of color-coded FFR values
for the entire coronary tree, derived from coronary angiogram data
that allow real-time review and interpretation of possible
atherosclerotic stenosis(es) intervention.
CathWorks CEO Jim Corbett said, "CPT code 0523T approval is a
very important step for our company and the market. The CPT code
decision also reflects the long-term clinical importance of
objective FFR-based PCI decision-making. Creating a long-term
reimbursement solution to support intraprocedural FFRangio™ will
enable physicians, patients, and payers to realize the proven
clinical and economic benefits of FFR on an every-case basis."
The CathWorks FFRangio™ System is in development and is not yet
FDA cleared.
About CathWorks
CathWorks is a medical technology company focused on applying
its advanced computational science platform to optimize PCI therapy
decisions and elevate coronary angiography from visual assessment
to an objective FFR-based decision-making tool for physicians.
FFR-guided PCI decision-making is proven to provide significant
clinical benefits for patients with coronary artery disease and
economic benefits for patients and payers. The company’s focus
today is specifically on bringing the CathWorks FFRangio™ System to
market to provide quick, precise, and objective intraprocedural FFR
guidance that is practical for every case.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180711005114/en/
CathWorksJim Corbett, CEO+1
949.395.1214jim.corbett@cath.works